PLSHOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
PANACEA LIFE SCIENCES HOLDINGS, INC.
Financials through Q1 FY2024, quarter ended Mar 31, 2024Last filing: 10-Q on May 6, 2024
$0.07+0.00 (+5.45%)
Close on Oct 19, 2026
- Market cap
- $1.15M
- P/E (TTM)
- –
- Dividend yield
- –
Panacea Life Sciences statistics
Financials through Dec 31, 2023, price as of Oct 19, 2026, median of Medicinal Chemicals & Botanical Products companies for comparison
Valuation
| Measure | Panacea Life Sciences | Industry median |
|---|---|---|
| Market Cap | $1.23M | $166.30M |
| Enterprise Value | $1.11M | $87.12M |
| PS Ratio | 0.51 | 3.60 |
Enterprise value
| Measure | Panacea Life Sciences | Industry median |
|---|---|---|
| EV / Sales | 0.47 | 2.43 |
Income (trailing twelve months)
| Measure | Panacea Life Sciences | Industry median |
|---|---|---|
| Revenue | $2.38M | $57.94M |
| Gross Profit | $1.12M | $90.47M |
| Operating Income | -$5.55M | -$21.49M |
| Pretax Income | -$8.02M | -$14.72M |
| Net Income | -$8.02M | -$22.46M |
| EBITDA | -$5.55M | -$17.14M |
| EPS (Diluted) | -$0.48 | -$0.83 |
Margins
| Measure | Panacea Life Sciences | Industry median |
|---|---|---|
| Gross Margin | 47.0% | 52.3% |
| Operating Margin | -232.5% | -44.5% |
| Pretax Margin | -336.1% | -13.0% |
| Profit Margin | -336.1% | -39.2% |
| EBITDA Margin | -232.5% | -31.3% |
| FCF Margin | -66.7% | -8.85% |
Returns
| Measure | Panacea Life Sciences | Industry median |
|---|---|---|
| Return on Assets (ROA) | -42.8% | -41.0% |
Growth
| Measure | Panacea Life Sciences | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 46.6% | 6.01% |
| Revenue Growth (3Y CAGR) | -35.8% | 2.25% |
Balance sheet
| Measure | Panacea Life Sciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $115.86K | $62.64M |
| Net Cash (Debt) | $115.86K | $15.77M |
| Net Cash Per Share | $0.01 | $0.66 |
| Equity (Book Value) | -$8.29M | $48.61M |
| Book Value Per Share | -$0.47 | $1.36 |
| Tangible Book Value | -$14.32M | $23.01M |
| Working Capital | -$14.79M | $75.09M |
Financial position
| Measure | Panacea Life Sciences | Industry median |
|---|---|---|
| Current Ratio | 0.24 | 3.30 |
| Quick Ratio | 0.02 | 2.39 |
| Interest Coverage | -3.56 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Panacea Life Sciences | Industry median |
|---|---|---|
| Operating Cash Flow | -$1.52M | -$12.39M |
| Capital Expenditures | -$65.32K | -$1.07M |
| Free Cash Flow | -$1.59M | -$20.34M |
| FCF Per Share | -$0.09 | -$0.42 |
Efficiency
| Measure | Panacea Life Sciences | Industry median |
|---|---|---|
| Asset Turnover | 0.13 | 0.38 |
| Inventory Turnover | 0.30 | 2.67 |
| Revenue Per Employee | $59.62K | $398.96K |
| Profits Per Employee | -$200.38K | -$705.27K |
| Employee Count | 40 | 74 |
Dividends and yields
| Measure | Panacea Life Sciences | Industry median |
|---|---|---|
| Earnings Yield | -652.7% | -22.8% |
| FCF Yield | -129.4% | -9.02% |
Shares
| Measure | Panacea Life Sciences | Industry median |
|---|---|---|
| Shares Outstanding | 17,645,400 | 58,139,000 |
| Shares Change (YoY) | 11.9% | 11.1% |
| Float | 17,645,400 | 49,154,900 |
| Shares Held by Insiders | 0.00% | 11.6% |
Scores
| Measure | Panacea Life Sciences | Industry median |
|---|---|---|
| Altman Z-Score | -4.48 | -0.27 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Panacea Life Sciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.